Improved Gross Margins
Gross margin as a percent of revenue improved significantly to 27% in Q3 2024 from 23% in Q3 2023, marking a 4% increase. Year-to-date gross margin increased by 7% from 19% in 2023 to 26% in 2024.
Positive Adjusted EBITDA
Adjusted EBITDA was positive both for the quarter and the year, amounting to $1.4 million in Q3 2024, although down 56% from $3.2 million in Q3 2023.
Successful Financing and Uplisting
Completed an oversubscribed $6.6 million life financing and uplisted to TSX, strengthening the balance sheet and positioning for M&A opportunities.
Strong Sales Pipeline and Backlog
Sales pipeline remains robust at $400-$450 million with a backlog of $74.7 million, mostly earmarked for completion in 2025.
Safety Record
Maintained a strong safety performance with no medical or emergency injuries reported during the quarter.